Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cell, 2026. Verfasst von Carlos de la Calle-Fabregat und 2 weiteren Autor:innen. Beteiligte Einrichtung: Paris-Saclay University, Gustave Roussy, INSERM U1015, Villejuif, France. Hauptthemen laut MEDLINE: Mutation, Clonal Hematopoiesis, Neoplasms, DNA-Binding Proteins. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Clonal hematopoiesis (CH), an expansion of hematopoietic clones harboring somatic mutations, is common in patients with solid tumors and associates with poor outcomes. In this issue of Cancer Cell, a study shows that, in response to immunotherapy, TET2-mutant CH enhances macrophage antigen presentation and CD8⁺ T cell activation, thereby improving therapeutic efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Paris-Saclay University, Gustave Roussy, INSERM U1015, Villejuif, France.
- Paris-Saclay University, Gustave Roussy, INSERM U981, IHU PRISM National PRecISion Medicine Center in Oncology, 94805 Villejuif, France.
- Paris-Saclay University, Gustave Roussy, INSERM U1015, Villejuif, France. Electronic address: florent.ginhoux@gustaveroussy.fr.
Zitieren
APA
de la Calle-Fabregat, C., Bernard, E., & Ginhoux, F. (2026). When blood mutations turn beneficial. Cancer Cell. https://doi.org/10.1016/j.ccell.2025.11.004
Vancouver
de la Calle-Fabregat C, Bernard E, Ginhoux F. When blood mutations turn beneficial. Cancer Cell. 2026. doi:10.1016/j.ccell.2025.11.004
BibTeX
@article{delaCalleFabregat2026,
author = {de la Calle-Fabregat, Carlos and Bernard, Elsa and Ginhoux, Florent},
title = {When blood mutations turn beneficial},
journal = {Cancer Cell},
year = {2026},
doi = {10.1016/j.ccell.2025.11.004}
}
EUVIMED